Drugs / Autologous CD4 T-Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03020524 | Jan 2017 → Nov 2019 | HIV infectious disease | University of Pennsylvania | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CD4 T-Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03020524 ↗ |
| Modality | Cell therapy | “autologous CD4+ T-cells genetically modified with an HR2, C34-peptide conjugated to the CXCR4 N-terminus using a lentiviral vector” NCT03020524 ↗ |
| Route | Intravenous | “administered IV as a single dose” NCT03020524 ↗ |